Henry Ford Health

Henry Ford Health Scholarly Commons
Cardiology Articles

Cardiology/Cardiovascular Research

10-1-2022

Sex Differences in Management and Outcomes Among Patients
With High-Risk Pulmonary Embolism: A Nationwide Analysis
Ramy Sedhom
Michael Megaly
Ayman Elbadawi
George Yassa
Ido Weinberg

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles

Authors
Ramy Sedhom, Michael Megaly, Ayman Elbadawi, George Yassa, Ido Weinberg, Martha Gulati, and Islam Y.
Elgendy

ORIGINAL ARTICLE

Sex Differences in Management and
Outcomes Among Patients With High-Risk
Pulmonary Embolism: A Nationwide Analysis
Ramy Sedhom, MD, MS; Michael Megaly, MD, MS; Ayman Elbadawi, MD;
George Yassa, DO; Ido Weinberg, MD; Martha Gulati, MD, MS;
and Islam Y. Elgendy, MD
Abstract
Objective: To examine the sex differences in management and outcomes among patients with highrisk acute pulmonary embolism (PE).
Patients and Methods: The Nationwide Readmissions Database was used to identify hospitalizations
with high-risk PE from January 1, 2016, to December 31, 2018. Differences in use of advanced
therapies, in-hospital mortality, and bleeding events were compared between men and women.
Results: A total of 125,901 weighted hospitalizations with high-risk PE were identiﬁed during the study
period; 46.3% were women (n¼58,253). Women were older and had a higher prevalence of several
comorbidities and risk factors of PE such as morbid obesity, diabetes mellitus, chronic pulmonary disease,
heart failure, and metastatic cancer. Systemic thrombolysis and catheter-directed interventions were more
commonly used among women; however, mechanical circulatory support was less frequently used. Inhospital mortality was higher among women in the unadjusted analysis (30.7% vs 27.8%, P<.001) and
after propensity score matching (odds ratio [OR], 1.16; 95% conﬁdence interval [CI], 1.08 to 1.25; P<.001),
whereas the rates of intracranial hemorrhage and noneintracranial hemorrhage were not different. On
multivariate regression analysis, female sex (OR, 1.18; 95% CI, 1.15 to 1.21; P<.001) was independently
associated with increased odds of in-hospital mortality.
Conclusion: In this contemporary observational cohort of patients admitted with high-risk PE, women
had higher rates of in-hospital mortality despite receiving advanced therapies more frequently,
whereas the rate of major bleeding events was not different from men. Efforts are needed to minimize
the excess mortality observed among women.
ª 2022 Mayo Foundation for Medical Education and Research
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P

ulmonary embolism (PE) is a leading
cause of morbidity and is the third
common etiology of cardiovascular
mortality worldwide. The annual mortality
rate from acute PE in the United States in
2017 was estimated to be 4.1 to 4.5 deaths
per 100,000 population.1,2 Patients presenting with massive PE (deﬁned as those with
sustained hypotension, shock, or requiring
inotropic support) and submassive PE
(deﬁned as those without hypotension but
with evidence of right ventricular dysfunction or myocardial injury)3 have considerably higher mortality rates (ie, up to 14%
in submassive PE and more than 50% in

n
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massive PE).4-6 Traditionally, treatment of
massive PE involved the prompt restoration
of pulmonary perfusion via systemic thrombolysis, and surgical embolectomy in those
whom systemic thrombolysis has failed or
is contraindicated.7 In recent years, there
have been several advancements in the management of high-risk patients with the introduction of catheter-directed interventions
(CDIs) including catheter-directed thrombolysis (CDT) and catheter-directed embolectomy (CDE).8
Prior studies evaluating the sex differences in management and outcomes of acute
PE have primarily included all-comers
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irrespective of the severity. Those studies
have shown inconsistent ﬁndings depending
on the period and population examined. For
example, some earlier studies suggested
higher mortality in men compared with
women9-12; however, other recent studies
showed that mortality was not different13-18
or was even higher in women, especially in
the younger age group (25 to 64 years of
age).2,19,20 Importantly, none of these
studies focused on the high-risk patients
with acute PE. To better address these
knowledge gaps, we aimed to examine the
sex differences in presentation, management,
and outcomes among patients with high-risk
PE from a contemporary nationally representative dataset.
PATIENTS AND METHODS
Data Source
We used the Nationwide Readmissions Database (NRD), Healthcare Cost and Utilization
Project (HCUP) from the Agency for Healthcare Research and Quality for this analysis.
The NRD contains discharge data from 28
geographically dispersed US states, accounting for w60% of the total US resident population and 58.2% of all US hospitalizations.
We identiﬁed the cohort, procedures, and
outcomes using the International Classiﬁcation of Diseases, Tenth Revision, Clinical
Modiﬁcation (ICD-10-CM) and procedure
classiﬁcation system codes. The codes used
are summarized in Supplemental Table 1
(available online at http://www.mayoclinic
proceedings.org).
Study Population
We identiﬁed hospitalizations with any diagnosis of acute PE using ICD-10-CM for the
years 2016e2018. The high-risk PE cohort
was deﬁned as PE with one of the following:
mechanical ventilation, requirement for
vasopressor, cardiogenic shock, use of CDT
including ultrasound-facilitated CDT, CDE,
systemic thrombolysis, or surgical embolectomy (ie, the cohort included patients with
massive PE as well as some patients with
submassive PE who received CDI or required
mechanical ventilation).21,22 Admissions

with ST-segment elevation myocardial
infarction, acute ischemic stroke, acute
limb ischemia, and PE during pregnancy, labor or puerperium were excluded.
Patient and hospital-level variables provided by HCUP NRD were used to identify
demographics and baseline characteristics.
The Elixhauser method was used to assess
comorbidities.23 The other comorbidities
were identiﬁed using appropriate ICD-10CM codes (Supplemental Table 1). The
NRD is a publicly available database with
de-identiﬁed hospitalization records; therefore, this study was exempt from institutional review board approval.
Outcomes
The main outcome of interest was the difference in all-cause in-hospital mortality between women and men. The secondary
outcomes were the differences in length of
stay (LOS), intracranial hemorrhage (ICH)
and non-ICH bleeding events which
included respiratory tract hemorrhage (ie,
epistaxis, hemoptysis, and hemorrhage
from the respiratory passages), hemothorax,
gastrointestinal hemorrhage, retroperitoneal
bleeding, hematuria, hemarthrosis, hemopericardium, intraocular hemorrhage, and
unspeciﬁed postprocedural bleeding.
We also examined the differences in
the use of advanced therapies (ie, CDT,
CDE, surgical embolectomy, systemic
thrombolysis, and mechanical circulatory
support [MCS]). Mechanical circulatory
support included any of the following:
extracorporeal membrane oxygenation
(ECMO), intra-aortic balloon pump, and
Impella.
In addition, we examined the trends in
mortality across the 3 years by quarters.
The 30-day urgent readmissions rates were
also examined in the unadjusted cohort.
For the readmission rates, we excluded those
admitted in December of each calendar year
(30-day readmissions for hospitalizations in
December could not be obtained because
the NRD does not cross the calendar year)
and those who died during the index admission. We identiﬁed the proportion of urgent
30-readmissions due to PE and major
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bleeding using the ICD-10 procedural classiﬁcation system codes of the ﬁrst three
recorded readmission diagnoses.
Statistical Analysis
All analyses were conducted using the
appropriate weighting, stratifying, and clustering samples following HCUP regulations.24,25 Continuous variables were
summarized as medians and interquartile
ranges (IQR); (25th and 75th percentiles)
and compared with the Mann-Whitney U
test. Categorical variables were displayed as
numbers and percentages and compared
with Pearson’s c2 or Fisher exact tests. All
P values are two-sided with a signiﬁcance
threshold less than .05. Trend analysis was
performed using the Poisson regression
method.
We used propensity score matching to
account for the differences in the baseline
patient and hospital-related characteristics
and advanced therapies. We created two propensity score-matched groups (women vs
men) using a propensity score matching algorithm with multivariable logistic regression conditioned on 26 variables: age,
obesity, morbid obesity, anemia, hypertension, atrial ﬁbrillation, diabetes mellitus,
heart failure, carotid disease, chronic lung
disease, pulmonary circulation disease, coagulopathy, peripheral vascular disease, renal
failure, liver disease, history of coronary artery bypass graft, history of stroke, history
of myocardial infarction, solid tumors
without metastases, metastatic cancer, nonseptic shock, saddle PE, cor pulmonale, use
of vasopressors, hospital teaching status,
and hospital size. We used a nearestneighbor 1:1 matching algorithm without
replacement with a caliper width of 0.2 the
standard deviation (SD) of the logit of the
propensity score. The success of matching
was examined by comparing standardized
mean differences in the distribution of the
covariates between the two treatment strategies. Additionally, we performed a secondary
multivariable regression analysis for the unadjusted cohort to determine the independent variables associated with increased
risk in-hospital mortality. The model
1874
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included the following 24 variables: age, female sex, morbid obesity, anemia, hypertension, atrial ﬁbrillation, diabetes mellitus,
heart failure, chronic lung disease, pulmonary circulation disease, coagulopathy, renal
failure, liver disease, solid tumors without
metastases, metastatic cancer, cardiogenic
shock, saddle PE, cor pulmonale, hospital
size, and type of advanced therapies
(ie, CDT, CDE, systemic thrombolysis, surgical embolectomy, and MCS). All variables
were forced into the multivariable model using the enter method. Finally, we compared
in-hospital mortality between men and
women across different subgroups in the
propensity-matched cohort. Statistical analyses were performed using STATA software
for Windows (version 16.0. College Station,
TX: StataCorp LLC) and IBM SPSS Statistics
for Windows (version 27.0. Armonk, NY:
IBM Corp).
RESULTS
A total of 125,901 weighted hospitalizations
with high-risk PE were identiﬁed during the
study period; 58,253 (46.3%) were women.
Women were older (65 [IQR, 52-74] years
vs 62 [IQR, 52-72] years; P<.001) with higher
prevalence of morbid obesity (18.3% vs
12.3%; P<.001), diabetes mellitus (29% vs
28.3%; P¼.006), anemia (30% vs 23%;
P<.001), chronic pulmonary disease (28.5%
vs 26.4%; P<.001), heart failure (25.6% vs
24.6%; P<.001), and metastatic cancer
(8.5% vs 6.7%; P<.001), but lower prevalence
of coagulopathy (20.4% vs 21.5%; P<.001),
pulmonary circulation disease (51.5% vs
54.9%; P<.001), atrial ﬁbrillation (17.4% vs
20.9%; P<.001), renal failure (15.6% vs
17.3%; P<.001), liver disease (4.9% vs 6.4%;
P<.001), and peripheral vascular disease
(7.2% vs 8.5%; P<.001). The use of systemic
thrombolysis (18.3% vs 17.1%; P<.001),
CDT (17.3% vs 16.6%; P¼.002), and CDE
(4.1% vs 3.9%; P¼.03) was more common
among women. Women were less likely to
receive MCS (1% vs 1.3%; P<.001) whereas
the use of surgical embolectomy was not
different between both groups. The differences in demographics, comorbidities, and
hospital characteristics between both groups
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TABLE 1. Baseline Patients and Hospital Characteristics Among Women vs Men With High-risk PEa,b
Before matching
Women
(n¼58,253), n (%)
Median age (IQR), y
Comorbidities
Morbid obesity
Hypertension
Diabetes mellitus
Anemia
Coagulopathy
Pulmonary circulation disease
Chronic pulmonary disease
Atrial ﬁbrillation/ﬂutter
Heart failure
Prior MI
Prior PCI
Prior CABG
Prior stroke
Renal failure
Liver disease
Metastatic cancer
Solid tumor without metastases
Peripheral vascular disease

65 (52-74)

After matching

Men
(n¼67,648), n (%)
62 (52-72)

P
<.001

Women
(n¼16,004), n (%)
63 (51-74)

Men
(n¼15,920), n (%)
63 (53-72)

P
.03

(12.3)
(57.7)
(28.3)
(23)
(21.5)
(54.9)
(26.4)
(20.9)
(24.6)
(5.3)
(0.4)
(3.9)
(4.3)
(17.3)
(6.4)
(6.7)
(5)
(8.5)

<.001
.75
.006
<.001
<.001
<.001
<.001
<.001
<.001
<.001
.03
<.001
<.001
<.001
<.001
<.001
.04
<.001

2110
9472
4871
4110
3836
9045
4622
3547
4510
795
51
539
812
3170
1103
1283
906
1531

8133 (14)
9472 (16.3)
7926 (13.6)

9550 (14.1)
9550 (14.1)
8827 (13)

.430
<.001
.004

Hospital characteristics
Large hospital
Teaching hospital

37,099 (63.7)
44,538 (76.5)

43,682 (64.6)
52,744 (78)

.001
<.001

Treatment modalities
Systemic thrombolysis
Surgical embolectomy
CDT
CDE
US-facilitated CDT

10,665
768
10,054
2396
2411

(18.3)
(1.3)
(17.3)
(4.1)
(4.1)

11,536
877
11,225
2620
2612

(17.1)
(1.3)
(16.6)
(3.9)
(3.9)

<.001
.747
.002
.030
.012

2688
239
2446
627
618

(16.8)
(1.5)
(15.3)
(3.9)
(3.9)

2570
209
2555
592
628

(16.1)
(1.3)
(16)
(3.7)
(3.9)

.30
.30
.23
.55
.80

Circulatory and ventilatory support
Vasopressors
4273
Mechanical ventillation
35,289
Mechanical circulatory support
562
Impella
180
ECMO
82
IABP
324

(7.3)
(60.6)
(0.96)
(0.3)
(0.1)
(0.6)

4594
42,344
877
258
56
622

(6.8)
(62.6)
(1.3)
(0.4)
(0.1)
(0.9)

<.001
<.001
<.001
.031
.002
<.001

1286
10,147
182
44
25
119

(8)
(63.4)
(1.1)
(0.3)
(0.2)
(0.7)

1289
10,135
252
73
22
180

(8.1)
(63.7)
(1.6)
(0.5)
(0.1)
(1.1)

.90
.77
.02
.06
.70
.01

Presentation and severity
Saddle PE
Acute cor pulmonale
Cardiogenic shock

10,645
33,690
16,901
17,486
11,888
30,018
16,598
10,151
14,927
1893
207
1036
2763
9073
2874
4977
2764
4185

(18.3)
(57.8)
(29)
(30)
(20.4)
(51.5)
(28.5)
(17.4)
(25.6)
(3.2)
(0.4)
(1.8)
(4.7)
(15.6)
(4.9)
(8.5)
(4.7)
(7.2)

8335
39,064
19,148
15,586
14,547
37,162
17,868
14,120
16,629
3581
294
2629
2928
11,671
4342
4535
3378
5721

(13.2)
(59.2)
(30.4)
(25.7)
(24)
(56.5)
(28.9)
(22.2)
(28.2)
(5)
(0.3)
(3.4)
(5.1)
(19.8)
(6.9)
(8)
(5.7)
(9.6)

2130
9537
4908
4155
3779
8909
4515
3604
4311
878
71
615
748
3027
1130
1193
850
1341

(13.4)
(59.9)
(30.8)
(26.1)
(23.7)
(56)
(28.4)
(22.6)
(27.1)
(5.5)
(0.4)
(3.9)
(4.7)
(19)
(7.1)
(7.5)
(5.3)
(8.4)

.73
.39
.60
.59
.75
.51
.49
.51
.15
.16
.18
.10
.34
.20
.61
.24
.38
.02

2415 (15.1)
2504 (15.6)
2353 (14.7)

2326 (14.6)
2430 (15.3)
2311 (14.5)

.43
.54
.76

10,038 (62.7)
12,314 (76.9)

9939 (62.4)
12,117 (76.1)

.72
.22

CABG ¼ coronary artery bypass surgery; CDE ¼ catheter-directed embolectomy; CDT ¼ catheter-directed thrombolysis; ECMO ¼ extracorporeal membrane
oxygenation; IABP ¼ intra-aortic balloon pump; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; PE ¼ pulmonary embolism; US ¼ ultrasound.
b
Large hospitals were deﬁned based on Healthcare Cost and Utilization Project deﬁnition which is based on hospital beds and are speciﬁc to the hospital’s location and
teaching status (https://www.hcup-us.ahrq.gov/db/vars/hosp_bedsize/nisnote.jsp) as follows; Northeastern region: rural 100; urban nonteaching 200, and urban teaching
425 beds. Midwest region: rural 50, urban nonteaching 175, and urban teaching 375 beds. Southern region: rural 75, urban nonteaching 200, and urban teaching
450 beds. Western region: rural 45, urban nonteaching 175, and urban teaching 325 beds.
a

are shown in Table 1. After propensity score
matching, 31,924 weighted hospitalizations
were included (women, n¼16,004; men,

n¼15,920). The differences in baseline and
hospital characteristics between those who
were and were not included in the propensity

Mayo Clin Proc. n October 2022;97(10):1872-1882 n https://doi.org/10.1016/j.mayocp.2022.03.022
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on November 22, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

1875

MAYO CLINIC PROCEEDINGS

On subgroup analysis, adjusted all-cause
in-hospital mortality rates were not different
between women and men in those aged
greater than 65 years (adjusted OR, 1.05;
95% CI, 0.95 to 1.17; P¼.30), presenting
with cardiogenic shock (adjusted OR, 1.08;
95% CI, 0.91 to 1.29; P¼.35), receiving systemic thrombolysis (adjusted OR, 1.10; 95%
CI, 0.90 to 1.34; P¼.37), and receiving surgical embolectomy (adjusted OR, 0.74; 95% CI,
0.38 to 1.45; P¼.38). However, adjusted allcause in-hospital mortality was higher among
women receiving CDT (adjusted OR, 1.51;
95% CI, 1.04 to 2.20; P¼.03) and CDE
(adjusted OR, 2.57; 95% CI, 1.51 to 4.36;
P<.001) (Supplemental Table 3, available online at http://www.mayoclinicproceedings.
org).

score analysis are shown in Supplemental
Table 2 (available online at http://www.
mayoclinicproceedings.org).

Outcomes
In the unadjusted analysis, the rate of allcause in-hospital mortality was higher
among women (30.7% vs 27.8%; P<.001).
In-hospital mortality has decreased among
women (34.3% in 2016 Q1 vs 28.9% in
2018 Q4; P trend<.001) and men (30.1%
in 2016 Q1 vs 26.4% in 2018 Q4; P
trend<.001) during the study period
(Figure 1).
The rate of ICH was lower among
women compared with men (3.1% vs 3.7%;
P<.001) but the rate of non-ICH bleeding
events did not differ between both sexes
(28% vs 27.9%; P¼.68). The LOS was
shorter among women (8 [IQR, 4-16] days
vs 9 [IQR, 4-20] days; P<.001) (Table 2).
After propensity score matching, the rate
of all-cause in-hospital mortality remained
signiﬁcantly higher among women (32.5%
vs 29.3%; odds ratio [OR], 1.16; 95% CI,
1.08 to 1.25; P<.001). There was no difference in the rates of ICH and non-ICH
bleeding events as shown in Table 2 and
the Supplemental Figure (available online
at http://www.mayoclinicproceedings.org).

Variables Independently Associated With
In-hospital Mortality
On multivariate regression analysis, female
sex was independently associated with
increased odds of in-hospital mortality
among admissions with high-risk PE (OR,
1.18; 95% CI, 1.15 to 1.21; P<.001). Other
variables associated with increased in-hospital mortality included age, diabetes mellitus,
heart failure, pulmonary circulation disease,
liver and kidney diseases, metastatic cancer,
coagulopathy, and cardiogenic shock. Use

Trends in in-hospital mortality
40%
35%
30%
25%
20%
15%
10%
5%

Males (P<.001)

Q
4
20

18

Q
3
20

18

Q
2
20
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Q
1
18

Q
4
20

20

17

Q
3
17

Q
2
20

20

17

Q
1
17

Q
4
20

20

16

Q
3
16

Q
2
20

16
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20

16

Q
1

0%

Females (P<.001)

FIGURE 1. National trends of in-hospital mortality among women versus men with high-risk pulmonary
embolism.
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Unadjusted incidences, n (%)
Outcomes

Women (58,253)

Propensity-matched incidences, n (%)

Men (67,648)

P

Women (16,004)

Men (15,920)

Odds ratio

95% CI

P

In-hospital mortality

17,871 (30.7)

18,839 (27.8)

<.001

5,202 (32.5)

4,657 (29.3)

1.16

1.08, 1.25

<.001

Cardiac arrest

10,339 (17.7)

10,981 (16.2)

<.001

3,042 (19)

2,726 (17.1)

1.13

1.04,1.23

.003

Discharge to a facility

14,935 (25.6)

17,041 (25.2)

.07

4,064 (25.4)

4,025 (25.3)

1.01

0.94, 1.08

.87

ICHb

1,784 (3.1)

2,484 (3.7)

<.001

517 (3.2)

555 (3.5)

0.92

0.76, 1.12

.43

Non-ICH
Respiratory tract hemorrhagec
Hematuria
Gastrointestinal bleeding
Hemarthrosis
Retroperitoneal bleeding
Hemothorax
Hemopericardium
Intraocular hemorrhage
Unspeciﬁed postprocedural
bleeding

2,447 (4.2)
1,305 (2.2)
4,135 (7.1)
547 (0.9)
954 (1.6)
379 (0.7)
88 (0.2)
20 (0)
449 (0.8)

3,447 (5.1)
2,515 (3.7)
5,196 (7.7)
477 (0.7)
970 (1.4)
628 (0.9)
79 (0.1)
14 (0)
502 (0.7)

<.001
<.001
<.001
<.001
.003
<.001
.10
.17
.56

659 (4.1)
339 (2.1)
1,235 (7.7)
169 (1.1)
322 (2)
140 (0.9)
33 (0.2)
NR
128 (0.8)

811 (5.1)
617 (3.9)
1,305 (8.2)
117 (0.7)
230 (1.4)
168 (1.1)
18 (0.1)
NR
118 (0.7)

0.80
0.54
0.94
1.44
1.40
0.83
1.82
0.83
1.08

0.68,
0.43,
0.82,
0.99,
1.05,
0.57,
0.74,
0.13,
0.73,

.006
<.001
.34
.06
.02
.32
.18
.81
.69

0.94
0.66
1.07
2.13
1.87
1.20
4.65
4.92
1.59

Blood transfuison

9,916 (17)

9,799 (14.5)

<.001

2,865 (17.9)

2,433 (15.3)

1.21

1.12, 1.32

<.001

Non-ICH or blood transfusion

16,320 (28)

18,880 (27.9)

.68

4,681 (29.2)

4,611 (29)

1.01

0.94, 1.09

.72

8 (4-16); 13.3 (17.5)

9 (4-20); 15.3 (20.1)

<.001

8 (4-17); 14.3 (19.4)

9 (4-19); 15.3 (20.3)

Median LOS, (IQR); days, mean (SD), days

<.001

ICH ¼ intracranial hemorrhage; LOS ¼ length of stay; NR¼ not reportable.
Non-ICH bleeding included respiratory tract hemorrhage, hemothorax, gastrointestinal hemorrhage, retroperitoneal bleeding, hematuria, hemarthrosis, hemopericardium, intraocular hemorrhage and unspeciﬁed postprocedural
bleeding.
c
Respiratory tract hemorrhage: epistaxis, hemoptysis, and hemorrhage from the respiratory passages.
a

b
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TABLE 2. In-hospital Outcomes Among Women vs Men With High-risk Pulmonary Embolisma
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Age

1.022 (1.021, 1.023)

Female sex

1.18 (1.15, 1.21)

Large hospital

0.98 (0.95, 1.00)

Hypertension

0.86 (0.84, 0.89)

Diabetes Mellitus

1.07 (1.04, 1.10)

Anemia

0.77 (0.74, 0.79)

Morbid obesity

0.94 (0.91, 0.98)

Atrial fibrillation

1.09 (1.05, 1.12)

Heart failure

1.09 (1.05, 1.12)

Pulmonary circulation disease

1.12 (1.09, 1.16)

Chronic lung disease

0.90 (0.87, 0.93)

Liver disease

1.19 (1.13, 1.25)

Renal failure

1.35 (1.30, 1.40)

Metastatic cancer

2.76 (2.64, 2.89)

Solid tumor without metastases

1.58 (1.49, 1.67)

Coagulopathy

1.34 (1.30, 1.38)

Saddle PE

0.70 (0.66, 0.74)

Cor pulmonale

0.89 (0.85, 0.93)

Cardiogenic shock

1.66 (1.59, 1.72)

Catheter-directed thrombolysis

0.12 (0.11, 0.13)

Catheter-directed embolectomy

0.43 (0.39, 0.47)

Systemic thrombolysis

0.41 (0.39, 0.43)

Surgical embolectomy

0.30 (0.26, 0.35)

Mechanical circulatory support

1.10 (0.98, 1.23)
0

0.5

1
Odd ratio

Decreased mortality

1.5

2

2.5

3

Increased mortality

FIGURE 2. Multivariate regression analysis representing the independent variables associated with in-hospital mortality in patients with
high-risk pulmonary embolism. PE, pulmonary embolism.

of CDT (OR, 0.12; 95% CI, 0.11 to 0.13;
P<.001), CDE (OR, 0.43; 95% CI, 0.39 to
0.47; P<.001), systemic thrombolysis (OR,
0.41; 95% CI, 0.33 to 0.43; P<.001), and
surgical embolectomy (OR, 0.30; 95% CI,
0.26 to 0.35; P<.001) were associated with
lower odds of in-hospital mortality
(Figure 2).

Urgent 30-Day Readmission Rates
The overall rate of urgent 30-day readmissions was 14.4% with a median time to readmission of 10 days (IQR, 4-18 days). Among
urgent readmissions, 8.8% were due to
recurrent PE, 5.5% due to non-ICH bleeding,
and 1.3% due to ICH. There was no
1878
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difference in the overall rate of urgent 30day readmissions (14.7% vs 14.2%; P¼.09),
readmissions due to recurrent PE (8.6% vs
9.1%; P¼.36), readmissions due to nonICH bleeding (5.4% vs 5.6%; P¼.74), and
readmissions due to ICH (1.2% vs 1.4%;
P¼.22) between women and men.

DISCUSSION
In this large nationwide observational analysis of w126,000 hospitalizations with
high-risk PE, we investigated the sex differences in management and outcomes. The
main ﬁndings of this study were as follows:
1) women were older and had a higher prevalence of some comorbidities and risk factors
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NRD
2016–2018
125,901 hospitalization with high-risk PE*

Risk profile
• Older age
• ↑ comorbidities

*Excludes pregnancy-related PE

In-hospital outcomes
• ↑ Mortality
• ↔ Major bleeding

vs

In-hospital management
• ↑ Systemic thrombolysis
• ↑ Catheter directed interventions
• ↓ Mechanical circulatory support

FIGURE 3. Summary of the ﬁndings of the study. NRD, nationwide readmission database; PE, pulmonary
embolism.

for PE such as morbid obesity, diabetes mellitus, anemia, chronic pulmonary disease,
heart failure, and metastatic cancer; 2)
women were more likely to receive systemic
thrombolysis, CDT, and CDE, but less MCS
compared with men; 3) the rates of inhospital mortality were higher among
women in both the unadjusted analysis and
after propensity score matching; 4) on multivariate regression analysis adjusting for patient and hospital characteristics, female
sex was independently associated with
higher odds of in-hospital mortality, whereas
the use of advanced therapies was associated
with lower odds of in-hospital mortality;
and 5) the rates of ICH and non-ICH
bleeding and urgent 30-day readmissions
were not different between both sexes
(Figure 3).
Among all-comers with PE irrespective
of the severity, some earlier studies have
shown that men had higher mortality
compared with women across different racial
groups in the United States9e11 and Japan.12
However, the results of recent studies have
been conﬂicting with some studies showing
similar mortality in both sexes,13-18 and
others have reported higher mortality among

women.19,20 Studies have also shown that
mortality from acute PE declined over time
in both men and women, but the decline
was less pronounced among women.11 The
current study shows that women admitted
with high-risk PE had higher rates of inhospital mortality compared with men,
even after adjusting for age and baseline
characteristics. Additionally, in-hospital
mortality in both sexes was high, highlighting that better risk stratiﬁcation tools
and therapies are needed to improve the
prognosis in this high-risk cohort.
Some reasons might explain the higher
rates of mortality among women and those
reasons could be related to the biological
(ie, sex) differences where women may
have different disease expression and/or responses to therapy. There are also sociocultural (ie, gender) factors where women
might be treated differently merely based
on their gender.26 Similar to prior
studies,14,15,20 our analysis showed that
women were older and had a higher prevalence of some comorbidities and risk factors
for PE. Women may have delayed presentation leading to a worse prognosis. Higher
pain tolerance or misinterpretation of the
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symptoms of PE by women might lead to
delay in seeking medical advice. Furthermore, the response to therapies might differ
between men and women. One study of patients with submassive PE has shown that
early systemic thrombolysis (<24 hours)
compared with heparin was associated with
lower 30-day mortality in men but not in
women.27 Additionally, the rates of major
bleeding were higher in women receiving
thrombolysis, although the rates of bleeding
were not different in our analysis. Mortality
was higher in women among those receiving
CDT or CDE in our study. Whether this is
related to women having smaller size pulmonary arteries28,29 is unclear.
In the current study, we did not observe a
signiﬁcant disparity in the use of advanced
therapies based on sex, aside from the lower
rates of using MCS in women. In another US
tertiary center analysis of all-comers with PE,
there was no difference in the use of CDT,
CDE, surgical embolectomy, and ECMO between both sexes.15 Other studies have also
shown similar rates of thrombolysis between
men and women.18-20 The role of CDI in the
treatment of PE is rapidly evolving.30 However, most of the trials examining CDI in acute
PE focused on right ventricular/left ventricular ratio as a surrogate marker for improved
short-term outcomes with no data on mortality beneﬁt.31 Societal guidelines recommend
systemic thrombolysis as the ﬁrst reperfusion
therapy in patients with high-risk PE,
whereas CDI is considered an alternative to
surgical embolectomy in patients who fail
or have a contraindication to systemic
thrombolysis.7,31e33 Our ﬁndings show that
advanced therapies were associated with
lower in-hospital mortality suggesting that
these therapies were associated with
improved outcomes in carefully selected patients with high-risk PE. We also found
that the use of MCS was lower in women
despite having similar rates of cardiogenic
shock to men. Our data are consistent with
prior analyses showing that women with
cardiogenic shock receive MCS less
frequently than men especially in the setting
of acute myocardial infarction.34e38 Clinicians may be hesitant to use large-bore
1880
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MCS in women given the increased risk of
vascular complications due to the smaller
caliber of the femoral artery.35,39
Although the rates of in-hospital
bleeding events were not different between
both sexes in our study, the sites of bleeding
differed. Men had higher rates of respiratory
tract hemorrhage and hematuria, whereas
women had higher rates of retroperitoneal
hemorrhage and blood transfusion. Intracranial hemorrhage was similar between both
sexes. Similar to our results, recent observational studies from the United States and
Japan found similar rates of major bleeding,
fatal bleeding, ICH, and blood transfusion
between both sexes.15,17 An analysis of the
Registro Informatizado de Enfermedad
TromboEmbolica (RIETE) registry found
that female sex was not an independent predictor of major bleeding following venous
thromboembolism.18 On the other hand, a
retrospective study from Spain found that
the 30-day risk of major bleeding in women
was w2 times higher than men,20 and a
recent meta-analysis showed that women
receiving anticoagulation for venous thromboembolism might be at a marginally higher
risk of major bleeding compared with men.40
However, this was not the case in our analysis in which the 30-day readmission rate
due to bleeding was not different between
both sexes.
Study Limitations
To the best of our knowledge, this study is
the ﬁrst to examine the sex differences in
management and outcomes of patients with
high-risk PE. The strengths of this investigation are driven by the large sample size with
national representation. However, the ﬁndings of this study should be interpreted in
the context of some limitations. First, this
study is a retrospective observational study
with its inherent limitation of selection
bias. We tried to mitigate that by performing
propensity score matching and multivariable
regression analyses. Second, given the
administrative nature of the NRD, the study
is subject to coding errors and data quality at
the site of collection, without the ability to
adjudicate accuracy. Additionally, the NRD
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uses discharge not admission diagnoses, so
we could not ascertain if PE was present
on admission or later during the course of
hospitalization. The NRD does not cross
the calendar year, so it is impossible to track
if the same patient was readmitted in a
different year. Third, we excluded any PE
occurring during pregnancy because this is
a sex-speciﬁc risk factor for PE. Although
this might be considered a limitation, it
removes the confounding of pregnancy
from this analysis. Fourth, the temporal relationship of certain outcomes cannot be reliably established. Fifth, data on discharge
medications d including anticoagulation
d and compliance are not available in the
NRD. In addition, the database lacks data
on the use of oral contraceptives or hormonal replacement therapy. Sixth, long-term outcomes, including long-term mortality and
bleeding, could not be assessed. Seventh,
the clinical reasoning for choosing one modality of advanced therapy vs the other could
not be determined, and the exact reason
behind the lower MCS use in women remains unclear. Finally, the NRD lacks data
on imaging and cardiac biomarkers which
could help better risk-stratify patients (especially those with submassive PE) and might
inﬂuence the decision regarding the use of
advanced therapies.
CONCLUSION
In this contemporary observational cohort of
patients admitted with high-risk PE, women
had higher rates of in-hospital mortality
despite receiving advanced therapies more
frequently, whereas the rate of major
bleeding events was not different from
men. The rates of in-hospital mortality did
not change in both sexes. These ﬁndings
have important implications, as we strive
for equitable care, irrespective of biological
sex. Efforts are needed to minimize the
excess mortality observed among women.
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